Moonmoon Kazi/LinkedIn
Jun 15, 2026, 12:46
Moonmoon Kazi: Climb Bio Presents Phase 1b ITP Trial Data at EHA 2026
Moonmoon Kazi, Sr. Medical Director at Climb Bio, shared a post on LinkedIn:
“It has been six months into my role at Climb Bio and I’m so grateful to be part of an organization with a clear, science‑driven vision for building a focused and differentiated pipeline.
Presenting preliminary data from our Phase 1b ITP trial was a meaningful milestone, reinforcing how thoughtful translational strategy and rigorous early clinical execution inform downstream pipeline decisions.
I’m energized by the clarity of purpose and the caliber of the team, and I look forward to helping advance programs with the potential to meaningfully impact patients.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome